Gallium-68 (Ga) prostate-specific-membrane-antigen positron-emission-tomography/computed-tomography is a highly promising method for imaging primary and recurrent prostate cancer. These dual-modality imaging technologies enable whole-body functional and anatomical evaluation in a single session. This study investigated the performance of Ga-prostate-specific-membrane-antigen-11 positron-emission-tomography/computed-tomography for detecting prostate carcinoma in patients with rising prostate-specific-antigen after primary therapy. Six hundred sixty (660) patients with biochemical recurrence referred for positron-emission-tomography/computed-tomography with Ga-prostate-specific-membrane-antigen-11 were evaluated retrospectively. Prostate-specific-antigen-stratified cohorts of pathological scan results were analyzed, and relationships between prostate-specific-antigen kinetics and PSMA-positive tumor lesions were correlated. Gallium-68 prostate-specific-membrane-antigen-11 positron-emission-tomography/computed-tomography showed a pathological prostate-specific-membrane-antigen uptake in 76% (500 of 660 patients). Positive scans were positively associated with prostate-specific-antigen (p<0.001). For patients with prostate-specific-antigen <0.2 ng mL, the PSMA-positive tumor lesions rate was 41%. Patients with prostate-specific-antigen of 0.2-<0.5 ng mL, 0.5-<1.0 ng mL, 1.0-<2.0 ng mL, and 2.0-<5.0 ng mL showed rates of 44.7%, 61.7%, 72.3%, 85.2%, respectively, and for prostate-specific-antigen of ≥5.0 ng mL it increased to 94%. Prostate-specific-antigen velocity was also correlated with PSMA-positive tumor lesions (p<0.001). In contrast, no association was found for prostate-specific-antigen doubling time (p=0.74). PSMA-positive tumor lesions were significantly increased in patients with primary intermediate- (Gleason Score7) and high-risk (Gleason Score>7) vs. low-risk prostate cancer (Gleason Score<7) (p<0.001). Our data confirm the high performance of Ga-prostate-specific-membrane-antigen positron-emission-tomography/computed-tomography for the detection of recurrent prostate cancer. This may alter treatment planning and has been documented in other studies as well.

中文翻译：

---

68Ga-PSMA-11正电子发射断层显像/计算机断层显像在大批前列腺癌生化复发患者中的诊断性能。

68镓（Ga）前列腺特异膜抗原正电子发射断层扫描/计算机断层扫描是一种对原发性和复发性前列腺癌成像的极有前途的方法。这些双模态成像技术可在单个会话中进行全身功能和解剖学评估。这项研究调查了Ga前列腺特异性膜抗原11正电子发射断层扫描/计算机断层扫描在初级治疗后检测前列腺特异性抗原升高的患者中检测前列腺癌的性能。回顾性评估了六百六十（660）名接受Ga-前列腺特异性膜抗原11正电子发射断层扫描/计算机断层扫描的生化复发患者。分析了前列腺特异性抗原分层的病理扫描结果队列，前列腺特异性抗原动力学与PSMA阳性肿瘤病变之间存在相关性。镓68前列腺特异性膜抗原11正电子发射断层扫描/计算机断层扫描显示76％的病理性前列腺特异性膜抗原摄取（660例患者中的500例）。阳性扫描与前列腺特异性抗原呈正相关（p <0.001）。对于前列腺特异性抗原<0.2 ng mL的患者，PSMA阳性肿瘤病变率为41％。前列腺特异性抗原为0.2- <0.5 ng mL，0.5- <1.0 ng mL，1.0- <2.0 ng mL和2.0- <5.0 ng mL的患者显示比率分别为44.7％，61.7％，72.3％，85.2％ ，并且对于≥5.0 ng mL的前列腺特异性抗原，它增加到94％。前列腺特异性抗原速度也与PSMA阳性肿瘤病变相关（p <0.001）。相反，没有发现前列腺特异性抗原加倍时间的相关性（p = 0.74）。相对于低危前列腺癌（Gleason Score <7），原发中度（Gleason Score7）和高危（Gleason Score> 7）患者的PSMA阳性肿瘤病变显着增加（p <0.001）。我们的数据证实了Ga前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在检测复发性前列腺癌方面的高性能。这可能会改变治疗计划，并且在其他研究中也有记录。我们的数据证实了Ga前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在检测复发性前列腺癌方面的高性能。这可能会改变治疗计划，并且在其他研究中也有记录。我们的数据证实了Ga前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在检测复发性前列腺癌方面的高性能。这可能会改变治疗计划，并且在其他研究中也有记录。